STAAR Surgical Company is facing heightened shareholder activism in the lead-up to its special meeting of stockholders scheduled for December 19, 2025. Broadwood Partners, L.P., which has increased its stake in STAAR to over 30% of outstanding shares, has taken an activist stance by threatening to pursue a proxy contest to remove three of STAAR’s six directors. This move could give Broadwood greater influence over the company without paying a control premium to other shareholders. Meanwhile, STAAR’s board has urged shareholders to vote in favor of the proposed merger with Alcon Inc., which offers $30.75 per share in cash, representing a 74% premium to STAAR’s 90-day volume-weighted average price as of August 4, 2025. The company’s leadership has emphasized the certainty and immediate value of the Alcon transaction amid ongoing shareholder activism.